Sodium nitroprusside for advanced heart failure. A metanalysis of literature data.

Abstract

Advanced heart failure (HF) is associated with a very poor prognosis and places a big burden on health-care services. The gold standard treatment, i.e. long-term mechanical circulatory support or heart transplantation, is precluded in many patients but observational studies suggest that the use of SNP might be associated with favourable long-term clinical outcomes. We performed a metanalysis of published studies that compared sodium nitroprusside (SNP) with optimal medical therapy to examine the safety and efficacy of SNP as part of the treatment regimen of patients hospitalized for advanced heart failure (HF). We searched PUBMED, EMBASE and WEB OF SCIENCE for studies that compared SNP with optimal medical therapy in advanced HF on July 2022. After screening 700 full-text articles, data from two original articles were included in a combined analysis. The analysis demonstrated a 66% reduction in the odds of death in advanced HF patients treated with SNP. The results show the potential importance of the inclusion of SNP in the treatment regimen of patients hospitalized because of advanced HF and underlines that controlled, randomized studies are still required in this condition.

• Authors: S Ghio, A Mandurino-Mirizzi, M T La Rovere, E Traversi, C Lombardi, L Scelsi, M Senni, A Iacovoni
• Journal: Vascular pharmacology (Vascul Pharmacol) Vol. 148 Pg. 107140 (02 2023) ISSN: 1879-3649 [Electronic] United States
• PMID: 36563732 (Publication Type: Meta-Analysis, Journal Article)
• Copyright: Copyright © 2022 Elsevier Inc. All rights reserved.

Chemical References

• Nitroprusside

Topics

• Humans
• Nitroprusside (adverse effects)
• Heart Failure (diagnosis, drug therapy)
• Prognosis